Nervonix Inc. to Present at Windhover Information and Medtech Insight's 'Investment in Innovation' Conference.

BOSTON -- Nervonix Inc. will be presenting on Thursday, October 21, 2004 at Windhover Information and Medtech Insight's Prestigious "Investment In Innovation" Event, taking place October 21-22, 2004 at the Westin Copley Place Hotel in Boston, Massachusetts.

Innovative Nerve Imaging Technology

NERVONIX, INC. is a development-stage medical device company which has invented and patented a break-through nerve imaging technology that operates non-invasively at the skin surface to accurately locate and image peripheral nerves (those outside the brain and spinal cord) in real time. Management believes that NERVONIX Nerve Imaging Technology will directly impact costs of care, procedure success rates, physician confidence and patient comfort in the Regional Anesthesia, Pain Management and Surgical Nerve Protection markets. Management further believes that the technology platform helps: (1) facilitate peripheral nerve block anesthesia for surgery and post-operative pain; (2) diagnose, treat, and document chronic pain; and (3) protect nerves during surgery. The NERVONIX device will operate non-invasively at the skin surface without firing the nerves. The Company seeks $1.6M to complete product development activities in advance of selecting a strategic partner to manufacture and market its products.

PRESENT TECHNOLOGY. At this time, location of nerves beneath the skin involves either noticeable electric shock in a trial and error search method at the skin surface or invasive means, such as use of a nerve stimulation needle or surgical visualization. The proprietary NERVONIX Nerve Imaging Technology is based on the ability of nerves to alter tissue distribution parameters of electrical fields. Since depolarization of the neuronal cell membrane is not required for this effect, extremely low-intensity electrical fields can be employed for image construction. Impedance changes measured at the skin surface are translated into data to pinpoint and construct a two-dimensional image of the underlying nerve structures, which appear in the form of peaks on a topographical map. The highest impedance levels show up as the brightest peaks on the map. The technology operates non-invasively and without any unpleasant sensations.

PRODUCT. The NERVONIX Nerve Imaging Technology is the basis for a flexible line of multiple nerve imaging products which can be implemented in several configurations to address different markets, applications and anatomy. The technology involves simple-to-manufacture and simple-to-operate equipment with devices readily adaptable to operating room, remote care, military and physician office use.

The basic offering is a sensor system applied to the skin surface. The sensor system is made up of a proprietary, disposable skin attachment system, which is applied non-invasively to the body surface. The sensor system is made up of proprietary electrode arrays with disposable designs. Software plugged into the sensor system translates impedance measurements in the form of an image for display on any laptop computer and/or hand-held imaging device. Power consumption needed to run the device consumes no more than a Blackberry device.

MARKETS. The NERVONIX Nerve Imaging products will address the Regional Anesthesia, Pain Management, and Surgical Nerve Protection markets. The total available 2005 market for the products, substantiated through independent studies, is $1.6BUS ($3.2B Worldwide). Initial users for the technology will include anesthesiologists, pain management specialists, and surgeons. As market penetration in these areas progresses, NERVONIX expects adoption by additional clinicians, including neurologists, family practitioners, internists, physiatrists, physical therapists, podiatrists, oral surgeons and ER physicians.

END USERS. Management believes that practitioners interested in painless, non-invasive identification of the course of peripheral nerves will be attracted to this technology. To summarize, these include anesthesiologists, surgeons, pain management specialists, neurologists, family practitioners, internists, physiatrists, physical therapists, podiatrists, oral surgeons, chiropractors and emergency room physicians.

INTELLECTUAL PROPERTY. The NERVONIX intellectual property portfolio is made up of issued patents and filed IP specific to Peripheral Nerve Management.

CORPORATE STRATEGY. Management believes that a highly capable commercial partner will reduce risk as this new technology enters the market and will permit the Company to move forward efficiently and expeditiously in developing and launching the NERVONIX family of nerve imaging products. Therefore, Management is in the process of selecting a strategic medical device partner with established distribution channels, marketing ability and sales processes in the NERVONIX target markets. The strategic partner will be given the opportunity to put its own product configuration together and set specification for final product development. In fact, the strategic partnership will be key to implementing all facets of launching the Company's first product, including decisions regarding manufacturing, a reimbursement strategy, and sales and marketing.

MANAGEMENT.

Paul L. Ray, President & CEO - With over 32 years of experience in the medical industry; with an emphasis on medical devices and diagnostics, Paul is the perfect fit for NERVONIX, Inc. Paul currently serves as a director on several corporate boards. As President, CEO and Chairman of Image Guided Technologies, Inc. (Nasdaq, IGTI), Paul guided the growth of the Boulder, Colorado company in seven years from venture capital start-up, through an IPO, to its sale in 2000 to Stryker Corporation. In addition to his corporate responsibilities, Paul has been a very active participant in Colorado's venture community. He served as a Director and Audit Committee Chairman for the University of Colorado Technology Corporation (UTC) from 1994 to 2000. Paul has served as Chairman of The Colorado Advanced Technology Institute (CATI). In 1999, Paul was appointed to the position of Co-Vice Chairman of the Governor's Commission on Science and Technology for the State of Colorado. In March 2003, he accepted the position of Director of The Office of Life Sciences and Biotechnology for the State of Colorado. Paul holds a Bachelor of Science in Business Administration from Ball State University.

Joan Cory, Ph.D. is V.P. and CTO - Joan has more than twenty years experience in basic and clinical research, directing medical school courses and special programs, biomedical consulting, and coordinating design, implementation, and supervision of biological safety laboratories. She has actively contributed to NERVONIX intellectual property, and currently oversees product development, IP, and clinical studies activities for the company. Joan also sits on the Board for Nervonix, Inc.

Philip Cory, M.D. is V.P. and Medical Director - In addition to inventing nerve imaging technology and co-founding the company, Phil is Board-certified in Anesthesiology and Pain Management. His nearly twenty-five years in the medical industry in academic and private practice settings form the basis for the business opportunity. As the company's medical director, he oversees the acquisition of clinical data while maintaining a hands-on approach to furthering the development of NERVONIX Nerve Imaging Technology. He continues to maintain a part-time anesthesiology practice. Philip also sits on the Board for Nervonix, Inc.

About Medtech Insight

Medtech Insight's "Investment In Innovation" conferences are considered the premier forum for senior executives in the investment and medical technology community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. Medtech Insight, which was recently acquired by Windhover Information Inc. (www.windhover.com), publisher of IN VIVO: The Business & Medicine Report, Start-UP: Windhover's Review of Emerging Technologies, and IN VIVO EuropeRx, offers a wide variety of products and services for the medical technology executive. In addition to conferences, the company publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, as well as analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the Boston conference or for more information on Medtech Insight, please call Scott Pantel at [phone] or [phone] toll-free in the U.S., e-mail [e-mail], or visit http://www.medtechinsight.com/in3-12.html.